Navigation Links
ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
Date:6/24/2009

BLACK MOUNTAIN, N.C., June 24 /PRNewswire/ -- ALP Life Sciences, LLC (Company) today announced the Nanoveson(TM) patent has been filed and the Nanoveson(TM) whitepaper is available at www.ALPLifeSciences.com/wp. After completing initial research, the Company is pursuing clinical trials and FDA regulatory approval of Nanoveson(TM) as a prescription drug treatment for non-alcoholic fatty liver disease (NAFLD).

Over 60 million adult Americans suffer from NAFLD and these numbers are rising rapidly. There is no FDA approved NAFLD treatment. NAFLD is a global health crisis. NAFLD is also associated with the metabolic syndrome and other life threatening diseases. NAFLD is known to progress to more advanced liver diseases such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and liver cancer.

Nanoveson(TM) is a novel approach to treating and diagnosing liver diseases and comorbid diseases utilizing the principles of Applied Lipid Polymorphism, which includes a revolutionary application of nanobiotechnology in the area of self-organizing lipid membranes. Nanoveson(TM) therapy utilizes only natural compounds. The therapy triggers liver triglyceride remodeling into bile phospholipids and lipid membrane fusion and aggregation in the intestines. Molecular compounds including biliary phospholipids, arachidonic acid metabolites, cholesterol, methyl metabolites, phthalate esters, and other compounds sequestered in vesicle membranes are expected to be a rich source of disease state biomarkers. Nanoveson(TM) also has the potential to provide extensive support to the life sciences industry in the area of drug metabolism testing.

Research has demonstrated that enterohepatic circulation is the mechanism that maintains quantitative whole body homeostasis of arachidonic acid. There is extensive research focused on blocking arachidonic acid metabolism along cytochrome P450, leukotriene, prostaglandin, and thromboxane eicosanoid pathways. Arachidonic acid metabolism is implicated in many inflammatory diseases, including cardiovascular diseases, gastrointestinal diseases, arthritis, asthma, diabetes and cancer. Nanoveson(TM) therapy may improve enterohepatic circulation by removing excess triglyceride deposits in the liver and improving bile flow; having a positive therapeutic impact on arachidonic acid driven disease states by reducing arachidonic acid availability for inflammatory metabolism. Orphan disease indication targets for inflammatory diseases may be pursed through clinical trials focused on arachidonic acid specific surrogate end points.

David K. Barker, Founder and CEO of ALP Life Sciences, LLC stated, "The preliminary evidence for the Nanoveson(TM) hypotheses is very promising, however, it should be emphasized that the complex mechanisms of action triggered by Nanoveson(TM) must be quantified, and the efficacy for targeted indications must be established by clinical trials." Barker added, "I'd like to take this opportunity to acknowledge the many scientists and physicians referenced in the Nanoveson(TM) whitepaper. Without their dedication to medical research the preliminary research and hypotheses presented in the Nanoveson(TM) whitepaper would not have been possible. However, nothing in this release or in the whitepaper suggests referenced researchers endorse the preliminary conclusions presented at this time."

ALP Life Sciences, LLC is a life sciences research and development company focused on therapeutics and diagnostics based on the new and emerging science of Applied Lipid Polymorphism. ALP Life Sciences, LLC is currently evaluating strategic relationships in the area of principal investigators, clinical trial facilities, medical school research partnerships, manufacturing, commercialization, global licensing and partnering opportunities for therapy, diagnostics and drug metabolism testing. Relationships with medical research foundations, public institutes of health, and life sciences venture capital firms are also being evaluated. Interested parties should contact ALP Life Sciences, LLC.


'/>"/>
SOURCE ALP Life Sciences, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat
2. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
3. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
4. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
5. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Redwood Scientific Technologies, Inc. ... product designed to help women balance their hormones. This ... technology. Jason Cardiff , President and ... able to help the millions of women across the ... effects of imbalanced hormones. Our research and development team ...
(Date:2/5/2016)... Ontario , Feb. 5, 2016  Aralez Pharmaceuticals ... combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ... POZEN and shareholders of Tribute. The combined company will ... pharmaceutical company with operations in Canada ... the United States . Under the terms of ...
(Date:2/5/2016)... -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ... markets and sells medical devices and wearable sleep ... and international markets, today announced its corporate and ... Company,s resources to develop its mobile health business, ... more on its major businesses. As of this ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... ... the company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability ... in design and manufacturing not only reduce the weight of the unit, they ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Looking for a ... be at the tips of your toes. Foot massage, whether administered by a professional ... comfort and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) ...
(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... ... 2016 , ... The American public tends to feel uncomfortable about drinking recycled ... municipal or well water. The recent experience with lead contaminated water in Flint, Michigan, ... way toward increasing public acceptance of recycled waste water as drinking water. , ...
Breaking Medicine News(10 mins):